within Pharmacolibrary.Drugs.ATC.J;

model J05AP13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AP13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ravidasvir is an investigational direct-acting antiviral agent that functions as an NS5A inhibitor. It has been principally studied for the treatment of chronic hepatitis C virus (HCV) infection, generally in combination with other antivirals (such as sofosbuvir). As of 2024, ravidasvir has not been approved by major regulatory agencies (such as FDA or EMA), but has been utilized in clinical trials, especially in developing countries.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for healthy adult subjects based on information from clinical trials (primarily ALIGN and STORM-C-1 studies), since no specific comprehensive publication reporting detailed compartmental PK parameters is available.</p><h4>References</h4><ol><li><p>Wu, G, et al., &amp; Shentu, J (2021). Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects. <i>Antimicrobial agents and chemotherapy</i> 65(10) e0060021–None. DOI:<a href=\"https://doi.org/10.1128/AAC.00600-21\">10.1128/AAC.00600-21</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34252301/\">https://pubmed.ncbi.nlm.nih.gov/34252301</a></p></li><li><p>Panjasawatwong, N, et al., &amp; Cressey, TR (2024). Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment. <i>Antimicrobial agents and chemotherapy</i> 68(7) e0000824–None. DOI:<a href=\"https://doi.org/10.1128/aac.00008-24\">10.1128/aac.00008-24</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38767383/\">https://pubmed.ncbi.nlm.nih.gov/38767383</a></p></li><li><p>Zhong, M, et al., &amp; Li, L (2016). Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor. <i>Bioorganic &amp; medicinal chemistry letters</i> 26(18) 4508–4512. DOI:<a href=\"https://doi.org/10.1016/j.bmcl.2016.07.066\">10.1016/j.bmcl.2016.07.066</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27506559/\">https://pubmed.ncbi.nlm.nih.gov/27506559</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AP13;
